Should family physicians follow the new ACC/AHA cholesterol treatment guideline? not completely: Why it is right to drop LDL-C targets, but wrong to recommend statins at a 7.5% 10-year risk

American Family Physician

Volumn 90, Issue 4, 2014, Pages 223-224

  Hayward, Rodney A ^a  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; EDITORIAL; EVIDENCE BASED PRACTICE; GENERAL PRACTITIONER; HEALTH PERSONNEL ATTITUDE; OVERALL SURVIVAL; PATIENT CARE; PRACTICE GUIDELINE; PUBLIC HEALTH; RISK ASSESSMENT; AGED; BLOOD; DRUG EFFECTS; FEMALE; FORECASTING; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MEDICAL SOCIETY; RISK FACTOR; STANDARDS; UNITED STATES;

AGED; AMERICAN HEART ASSOCIATION; CHOLESTEROL, LDL; FEMALE; FORECASTING; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PHYSICIANS, FAMILY; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; UNITED STATES;

EID: 84921803650     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl2):S1-S45.
2. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
3. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006;145(7):520-530.
4. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease [published correction appears in Ann Intern Med. 2011;154(12):848]. Ann Intern Med. 2010;152(2):69-77.
5. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. Circ Cardiovascular Qual Outcomes. 2012;5(1):2-5.
6. Sussman J, Vijan S, Hayward R. Using benefit-based tailored treatment to improve the use of antihypertensive medications. Circulation. 2013;128(21):2309-2317.
7. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590.
8. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
9. Quanstrum KH, Hayward RA. Lessons from the mammography wars. N Engl J Med. 2010;363(11):1076-1079.
10. Kerr EA, Hayward RA. Patient-centered performance management: enhancing value for patients and health care systems. JAMA. 2013;310(2):137-138.